Anti-CD19 CAR-T cell immunotherapy is a hopeful treatment option for patients with B cell lymphomas, however it copes with partly severe adverse effects like neurotoxicity. The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.